CC
SNDX icon

Commodore Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Commodore Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-885,000
Closed -$17M – 39
2024
Q3 		$17M Buy
885,000
+60,000
+7% +$1.24M 1.06% 27
2024
Q2 		$16.9M Buy
825,000
+506,149
+159% +$10.6M 1.16% 24
2024
Q1 		$7.59M Buy
+318,851
New +$7.11M 0.51% 33
2023
Q4 		– Sell
-957,509
Closed -$13.9M – 37
2023
Q3 		$13.9M Sell
957,509
-40,087
-4% -$758K 1.63% 21
2023
Q2 		$20.9M Buy
997,596
+143,712
+17% +$2.99M 2.35% 15
2023
Q1 		$18M Buy
853,884
+165,439
+24% +$4.12M 2.75% 12
2022
Q4 		$17.5M Sell
688,445
-49,665
-7% -$1.16M 2.64% 15
2022
Q3 		$17.7M Buy
+738,110
New +$16.6M 2.85% 13
2021
Q2 		– Sell
-236,500
Closed -$5.29M – 31
2021
Q1 		$5.29M Sell
236,500
-93,815
-28% -$2.12M 2.11% 22
2020
Q4 		$7.35M Buy
+330,315
New +$6.85M 3.99% 11

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Commodore Capital's SNDX Position: Q4 2024 in Review

Commodore Capital sold out of Syndax Pharmaceuticals (SNDX) in Q4 2024, closing a stake of 885,000 shares — an estimated $17M sold.

Commodore Capital first reported a position in SNDX in Q4 2020 and held it in 10 quarters. The position peaked at $20.9M in Q2 2023. 215 funds tracked by Wall St. Rank hold SNDX as of Q4 2024.

  • Commodore Capital reported no remaining Syndax Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Commodore Capital sold 885,000 Syndax Pharmaceuticals shares in Q4 2024, an estimated $17M.
  • Commodore Capital first reported a position in Syndax Pharmaceuticals in Q4 2020 and held it in 10 quarters.
  • Commodore Capital's Syndax Pharmaceuticals position peaked at $20.9M in Q2 2023.
  • 215 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2024.

Based on Commodore Capital's 13F filing for Q4 2024, filed 14 Feb 2025.